|
5.5.1 ASCO (GÉNÉRAL)
|
|
|
|
5.5.10 ASCO (HÉMATO)
|
|
|
|
|
|
|
5.5.13 ASCO (DIVERS)
|
|
|
|
|
|
5.5.13.3 ASCO (DIVERS-CHIRURGIE)
|
|
|
|
5.5.14 ASCO (VESSIE)
|
|
|
|
|
|
|
|
|
5.5.15 ASCO (BIOPSIES LIQUIDES)
|
|
|
|
5.5.16.1 ASCO (MÉDECINE DE PRÉCISION-TRK/RET)
|
|
|
|
|
|
|
5.5.16.3 ASCO (MÉDECINE DE PRÉCISION-KRAS)
|
|
|
|
Early cancer drug data give Amgen hope it has 'cracked KRAS code' [Biopharma Dive]
|
|
|
|
|
|
Amgen's drug, called AMG 510, is the first of its kind to reach clinical testing. It works by binding to what the company describes as a "hidden groove" on the protein produced by the mutated KRAS gene. With AMG 510 locked on, the protein is inactivated, in theory shutting down the signals it sends to trigger cell division and tumor growth.
|
|
|
|
|
|
|
|
|
|
5.5.2 ASCO (SEIN)
|
|
|
|
5.5.4 ASCO (IMMUNOTHÉRAPIES)
|
|
|
|
|
5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)
|
|
|
|
5.5.6 ASCO (PEAU-MÉLANOME)
|
|
|
|
|
5.5.7 ASCO (GYNÉCO)
|
|
|
|
|
5.5.8 ASCO (POUMON)
|
|
|
|
|
|
5.5.9 ASCO (AUTRES ORGANES)
|
|
|
|
|